VistaGen Therapeutics (VTGN) versus The Competition Critical Analysis

VistaGen Therapeutics (NASDAQ:VTGN) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare VistaGen Therapeutics to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.

Valuation and Earnings

This table compares VistaGen Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
VistaGen Therapeutics	$2.50 million	-$69.68 million	-0.10
VistaGen Therapeutics Competitors	$727.61 million	$12.25 million	-10.24

VistaGen Therapeutics’ rivals have higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares VistaGen Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
VistaGen Therapeutics Competitors	-9,051.23%	-201.20%	-30.64%

Analyst Ratings

This is a summary of recent ratings and recommmendations for VistaGen Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1	4	0	0	1.80
VistaGen Therapeutics Competitors	9792	15073	45355	1574	2.54

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 458.82%. As a group, “Biotechnology” companies have a potential upside of 96.34%. Given VistaGen Therapeutics’ higher probable upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than its rivals.

Risk & Volatility

VistaGen Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics’ rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Insider and Institutional Ownership

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

VistaGen Therapeutics rivals beat VistaGen Therapeutics on 8 of the 13 factors compared.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.